111, Inc. Sponsored ADR (NASDAQ:YI – Get Free Report) Director Yang Luke Chen sold 49,920 shares of the firm’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $0.23, for a total value of $11,481.60. Following the completion of the transaction, the director owned 539,462 shares in the company, valued at approximately $124,076.26. This trade represents a 8.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Yang Luke Chen also recently made the following trade(s):
- On Monday, June 15th, Yang Luke Chen sold 44,000 shares of 111 stock. The stock was sold at an average price of $0.23, for a total value of $10,120.00.
- On Wednesday, May 27th, Yang Luke Chen sold 3,400 shares of 111 stock. The stock was sold at an average price of $0.25, for a total value of $850.00.
- On Tuesday, May 26th, Yang Luke Chen sold 1,440 shares of 111 stock. The stock was sold at an average price of $0.27, for a total transaction of $388.80.
111 Stock Performance
NASDAQ YI opened at $4.41 on Friday. 111, Inc. Sponsored ADR has a one year low of $2.48 and a one year high of $11.17. The company’s 50 day moving average price is $5.76 and its 200 day moving average price is $5.68. The firm has a market capitalization of $38.76 million, a price-to-earnings ratio of -3.15 and a beta of 0.60.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on 111
About 111
111, Inc (NASDAQ: YI) is a leading online pharmacy e-commerce platform in China, operating under the brand 111.com. The company provides consumers with a comprehensive selection of pharmaceutical and healthcare products through its proprietary digital channels, including a website and mobile applications. By integrating online ordering, prescription management, and direct-to-consumer delivery, 111, Inc aims to streamline the purchase of medicines and health-related goods for customers nationwide.
111, Inc’s product portfolio encompasses prescription and over-the-counter drugs, nutritional supplements, vitamins, maternal and child care items, personal care products, and beauty goods.
See Also
- Five stocks we like better than 111
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for 111 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 111 and related companies with MarketBeat.com's FREE daily email newsletter.
